Phantom criteria for qualification of brain FDG and amyloid PET across different cameras
Yasuhiko Ikari(Japan Association for Development of Community Medicine), Michio Senda(Kyoto University), Kenji Ishii(Tokyo Metropolitan Institute of Gerontology), Takeshi Iwatsubo(National Center of Neurology and Psychiatry), Go Akamatsu(Foundation for Biomedical Research and Innovation), Kengo Ito(National Center for Geriatrics and Gerontology), Tomoyuki Nishio(Kindai University Hospital)
Cited by 59
Related Papers
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Lecanemab in Early Alzheimer’s Disease
|New England Journal of Medicine|2022|5k
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature
|Journal of Neuropathology & Experimental Neurology|2012|2.1k
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
|Nature|2018|1.7k
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
|The Journal of Prevention of Alzheimer s Disease|2022|1.3k